Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.
Couturier MA, Thomas X, Raffoux E, Huguet F, Berthon C, Simand C, Gallego-Hernanz MP, Hicheri Y, Hunault Berger M, Saillard C, Leguay T, Loiseau C, Béné MC, Chevallier P. Couturier MA, et al. Among authors: saillard c. Leuk Lymphoma. 2021 Mar;62(3):620-629. doi: 10.1080/10428194.2020.1844198. Epub 2020 Nov 6. Leuk Lymphoma. 2021. PMID: 33153370
National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
Saillard C, Crocchiolo R, Furst S, El-Cheikh J, Castagna L, Signori A, Oudin C, Faucher C, Lemarie C, Chabannon C, Granata A, Blaise D. Saillard C, et al. Leuk Lymphoma. 2014 May;55(5):1106-12. doi: 10.3109/10428194.2013.820285. Epub 2014 Feb 4. Leuk Lymphoma. 2014. PMID: 23822538
Histone deacetylase inhibitor abexinostat (S78454/PCI-24781) as a successful approach in a case of refractory peripheral angio-immunoblastic T-cell lymphoma, as a bridge to reduced intensity conditioning haplo-identical allogenic stem cell transplant.
Saillard C, El Cheikh J, Granata A, Coso D, Schiano JM, Bouabdallah R, Blaise D, Charrier N, Broussais F. Saillard C, et al. Leuk Lymphoma. 2016;57(3):714-6. doi: 10.3109/10428194.2015.1061190. Epub 2016 Jan 11. Leuk Lymphoma. 2016. PMID: 26750740 No abstract available.
PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome.
Passet M, Boissel N, Sigaux F, Saillard C, Bargetzi M, Ba I, Thomas X, Graux C, Chalandon Y, Leguay T, Lengliné E, Konopacki J, Quentin S, Delabesse E, Lafage-Pochitaloff M, Pastoret C, Grardel N, Asnafi V, Lhéritier V, Soulier J, Dombret H, Clappier E; Group for Research on Adult ALL (GRAALL). Passet M, et al. Among authors: saillard c. Blood. 2019 Jan 17;133(3):280-284. doi: 10.1182/blood-2018-10-882142. Epub 2018 Dec 3. Blood. 2019. PMID: 30510083 Free article. No abstract available.
Alternative Effective and Safe Induction Regimens for Newly Diagnosed Acute Myeloid Leukemia in Patients With Cardiac Contraindication to Anthracyclines.
Marcault C, Venton G, Gastaud L, Mannone L, Rey J, D'Incan E, Saillard C, Charbonnier A, Raynaud S, Vey N, Cluzeau T. Marcault C, et al. Among authors: saillard c. Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):e76-e81. doi: 10.1016/j.clml.2019.11.016. Epub 2019 Nov 26. Clin Lymphoma Myeloma Leuk. 2020. PMID: 31865004
Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients.
Malard F, Vekhoff A, Lapusan S, Isnard F, D'incan-Corda E, Rey J, Saillard C, Thomas X, Ducastelle-Lepretre S, Paubelle E, Larcher MV, Rocher C, Recher C, Tavitian S, Bertoli S, Michallet AS, Gilis L, Peterlin P, Chevallier P, Nguyen S, Plantamura E, Boucinha L, Gasc C, Michallet M, Dore J, Legrand O, Mohty M. Malard F, et al. Among authors: saillard c. Nat Commun. 2021 May 25;12(1):3084. doi: 10.1038/s41467-021-23376-6. Nat Commun. 2021. PMID: 34035290 Free PMC article. Clinical Trial.
Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study.
Kayser S, Schlenk RF, Lebon D, Carre M, Götze KS, Stölzel F, Berceanu A, Schäfer-Eckart K, Peterlin P, Hicheri Y, Rahme R, Raffoux E, Chermat F, Krause SW, Aulitzky WE, Rigaudeau S, Noppeney R, Berthon C, Görner M, Jost E, Carassou P, Keller U, Orvain C, Braun T, Saillard C, Arar A, Kunzmann V, Wemeau M, De Wit M, Niemann D, Bonmati C, Schwänen C, Abraham J, Aljijakli A, Haiat S, Krämer A, Reichle A, Gnadler M, Willekens C, Spiekermann K, Hiddemann W, Müller-Tidow C, Thiede C, Röllig C, Serve H, Bornhäuser M, Baldus CD, Lengfelder E, Fenaux P, Platzbecker U, Adès L. Kayser S, et al. Among authors: saillard c. Haematologica. 2021 Dec 1;106(12):3100-3106. doi: 10.3324/haematol.2021.278722. Haematologica. 2021. PMID: 34047178 Free PMC article.
Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients.
Garciaz S, Hospital MA, Alary AS, Saillard C, Hicheri Y, Mohty B, Rey J, D'Incan E, Charbonnier A, Villetard F, Maisano V, Lombardi L, Ittel A, Mozziconacci MJ, Gelsi-Boyer V, Vey N. Garciaz S, et al. Among authors: saillard c. Cancers (Basel). 2022 Apr 16;14(8):2025. doi: 10.3390/cancers14082025. Cancers (Basel). 2022. PMID: 35454930 Free PMC article.
121 results